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Abstract
Background: Acute otitis media (AOM) is a common painful infection in children, with around 2.8 million cases
presenting to primary care in England and Wales annually. Nearly all children who present to their general
practitioner (GP) with AOM or AOM with discharge (AOMd) are treated with orally administered antibiotics. These
can cause side effects; contribute to the growing problem of antimicrobial resistance, and more rarely, allergic
reactions. Alternative treatments, such as an antibiotic eardrops, or ‘delayed’ orally administered antibiotics, could
be at least as effective and safe as immediate orally administered antibiotics for children with AOMd.
Methods/design: REST is a pragmatic, three-arm, individually randomised, non-inferiority trial being conducted in
175 GP practices across the United Kingdom (UK). The study aims to recruit 399 children aged (≥ 12 months and <
16 years) presenting to their GP with AOMd. Children will be randomised to one of three arms: immediate
ciprofloxacin 0.3% eardrops; delayed orally administered amoxicillin (clarithromycin if penicillin allergic) or
immediate orally administered amoxicillin (clarithromycin).
Recruitment, including eligibility screening, randomisation and data collection, are conducted using the innovative,
TRANSFoRm electronic trial management platform. Integrated within the primary care electronic medical records it
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provides automatic eligibility checking, part-filling of e-CRFs, study workflow management and routine NHS follow-
up data collection. The primary outcome is time to resolution of all significant symptoms and will be collected by
the parent using a Symptom Recovery Questionnaire (SRQ). Secondary outcomes, including cost-effectiveness,
duration of moderately bad or worse symptoms and repeat AOMd episodes, will be collected at day-14 and at 3
months.
Discussion: It is unclear whether prescribing orally administered antibiotics to children with AOMd results in a
reduction in symptoms or a shorter duration of illness. The REST trial should allow us to compare the non-inferiority
of: immediate topically administered ciprofloxacin ear drops, or delayed orally administered amoxicillin
(clarithromycin) against immediate orally administered amoxicillin (clarithromycin). We aim to recruit 399 patients
from 175 practices in the UK. Using the TRANSFoRm software to randomise participants to the trial will enable
recruitment for a relatively uncommon condition.
Trial registration: Name of Registry: ISCRTN
Registration Number: ISRCTN12873692. This contains all items required to comply with the World Health
Organization Trial Registration Data Set
Date of Registration: 24 April 2018
Name of Registry: EudraCT
Registration Number: 2017-003635-10
Date of Registration: 6 September 2017
Keywords: Acute otitis media, Primary care, Antibiotics, Paediatrics, Randomised controlled trial
Background and rationale
Acute otitis media (AOM) is important to children, par-
ents and the National Health Service (NHS). Firstly, the
infection causes pain and distress to the child, disrupting
sleep and family routines. In around 15% of cases, a rise
in middle-ear pressure and/or inflammation weakening
the tympanic membrane results in it bursting, dischar-
ging pus from the middle ear as a discharge (otorrhoea)
[1]. Children with AOM and discharge (AOMd) have
similar levels of pain and are more unwell at presenta-
tion than children with AOM [2, 3]. Moreover, children
with AOMd have a worse prognosis, and higher rates of
pain at 1 week, as reported by parents (carers), repeat
AOM episodes and hearing problems at 3 months [2].
Estimates of parental costs (travel, over the counter
(OTC) medicines and lost earnings) vary [4–6], with
even the lowest suggesting £4million in England and
Wales per annum.
Over 90% of UK parents attend primary care health
services for each episode of AOMd [7], with over 150,
000 general practitioner (GP) consultations for AOMd
in England and Wales per annum at a cost to the NHS
of over £3 million [4, 5], which is more than for any
other common symptom of acute infection.
More children with AOM and AOMd receive an orally
administered antibiotic in the UK [8] and the United
States [9] than for any other respiratory infection, with
three quarters of GPs prescribing orally administered an-
tibiotics to at least 80% of children diagnosed as such
[10, 11]. Our 2015 audit, including 33 GP practices and
56,251 children, confirmed that immediate orally
administered antibiotics is usual care for AOMd: 88%
were given orally administered antibiotics of which 97%
were given immediately.
There is strong evidence that children with AOMd
benefit from immediate orally administered antibiotics.
The number needed to treat with antibiotics is three to
reduce the proportion of children with pain and/or fever
at 3–7 days compared with placebo/no treatment [3].
The National Institute for Health and Care Excellence
(NICE), therefore, recommends that immediate antibi-
otics should be considered [12]. Orally administered an-
tibiotics do, however, also cause side effects, are
associated with subsequent eczema and hay fever [13]
and with population [14] and patient-level [15] anti-
microbial resistance.
In response to the UK’s Antimicrobial Resistance Ac-
tion Plan calls for research to preserve antibiotic effects
[16] we have designed a trial of topically administered
antibiotics in children with AOMd, aiming to reduce the
use of systemic antibiotics. Perforation of the tympanic
membrane provides a portal of entry into the middle ear
for antibiotic drops instilled in the ear canal. In children
with ventilation tubes (‘grommets’), it has been shown
that topically administered antibiotics can reach the in-
fected middle ear despite purulent discharge [17], and
that compared with orally administered antibiotics, they
are more effective in reducing the duration of otorrhoea,
recurrence of AOM and have fewer side effects [17].
This study also showed that topically administered anti-
biotics are cost-effective [18]. However, further research
is needed in children with AOMd without grommets,
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since the opening to the middle ear may be smaller and
the tympanic membrane heals quickly, which could pre-
vent the drops from reaching the middle ear. If topically
administered and delayed antibiotics are shown to be
non-inferior, we also need to understand the acceptabil-
ity of such treatment to clinicians and parents and how
to address any barriers to implementation.
We will address this evidence gap by assessing the
clinical effectiveness and economic implications of im-
mediate topically vs. delayed orally administered antibi-
otics and testing the hypotheses: (1) immediate
antibiotics are better than placebo/no treatment for
AOMd symptoms [3] and (2) delayed orally adminis-
tered antibiotics are similar to immediate orally adminis-
tered antibiotics in children with AOM (though with
reduced antibiotic consumption) [1].
The REST study is a three-arm, randomised controlled
trial (RCT) investigating the clinical effectiveness and
economic implications of topically administered or de-
layed antibiotics compared with immediate orally admin-
istered antibiotics, powered for the duration and severity
of the symptoms most important to parents, while also
investigating adverse events, complications and AOM/
AOMd recurrence. By testing two interventions that
could reduce systemic antibiotic exposure (immediate
topically administered and delayed orally administered
antibiotics), this study is at the forefront of research to
improve antimicrobial stewardship in AOMd.
Methods/design
Aims and objectives
The key aim of this research is to investigate the clinical
effectiveness and economic impact of immediate topic-
ally or delayed orally administered antibiotics compared
with immediate orally administered antibiotics for symp-
tom duration in children presenting to primary care with
AOM with discharge (AOMd).
Secondary objectives are to:
 Estimate the short-term cost-implications of imme-
diate topically or delayed orally administered antibi-
otics compared with immediate orally administered
antibiotics from the perspective of the NHS
 Compare the effects on duration of ‘moderately bad
or worse’ symptoms; parent/legal guardian
satisfaction with treatment; and adverse events
 Compare hearing loss and rate of recurrence of
AOM/AOMd at 3 months
 Understand parent/legal guardian and clinician
views of participating in a trial about AOMd,
adherence and satisfaction with allocated treatment.
 Evaluate the impact of treatment on carriage of
antibiotic resistance in the gut
Trial design
This is a multi-site, pragmatic, three-arm, individually
randomised (stratified by age < 2 vs. ≥ 2 years), non-
inferiority, open trial. We compare (1) immediate top-
ically administered ciprofloxacin 0.3% drops with (2)
delayed orally administered antibiotics or (3) immedi-
ate orally administered antibiotic in children aged 12
months to 16 years with unilateral AOMd as the pre-
senting symptom of recent-onset (≤ 7 days) AOM.
The primary endpoint is collected by questionnaire at
day 14 post recruitment. Secondary outcomes are col-
lected both at 14 days and at 3 months by
questionnaire.
This study is classified as a Type A study (low risk) by
the Medicines and Healthcare Regulatory Agency
(MHRA), with regulatory approval obtained on 4 May
2018.
The trial design includes an internal pilot recruitment
phase of 6 months’ duration, primarily to verify that re-
cruitment was possible before progression to the main
phase of the trial.
The REST study utilises an integrated electronic trial
management platform, TRANSFoRm, that was initially
developed as part of the EU FP7 TRANSFoRm project
(2009–2015) and evaluated in a 60-site clinical trial in
Poland [19]. The system integrates as a plug-in within
the host Electronic Health Record (EHR) system through
the provider’s Application Programmer’s Interface (API).
The key features of the system include:
 Automated eligibility checking; the TRANSFoRm
plug-in allows the EHR opened during a consult-
ation to be automatically checked against the REST
eligibility criteria
 Consent – the TRANSFoRm platform allows the
clinician to print the study consent form for the
participant to sign a record of consent that can then
be entered onto the platform initiating the trial’s
workflow
 An integrated randomisation system for immediate
randomisation of participants during consultation
 Trial-specific Electronic Case Report Forms (eCRFs)
that are presented to clinicians at the appropriate
appointments to complete. Some trial data is
automatically retrieved from the SystmOne health
record and used to part-fill the trial eCRF, which
can be amended by the user
Upon submission of the eCRF the TRANSFoRm plat-
form automatically records a record of trial activity in
the participant’s health record. The study flow diagram
is provided in Fig. 1 and the Standard Protocol Items:
Recommendations for Interventional Trials (SPIRIT)
Checklist in Additional file 1.
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Setting
We aim to recruit 175 SystmOne GP practices from all
15 UK CRN’s. The Clinical Research Network (CRN) in-
vite research active SystmOne GP practices to express
an interest in taking part in the study.
GP practice set-up
Interested practices are sent a local document pack by
the study team and practices are asked to return a set of
documents including a CV, Good Clinical Practice
(GCP) certificates and a signed site contract. Sites
undergo remote training in trial conduct and the use of
the TRANSFoRm electronic platform.
A site is only greenlighted once all local documents
have been completed and the principal investigator (PI)
has completed the online training. At this point the
TRANSFoRm electronic platform is installed onto the
PI’s computer. Once a site is greenlighted, additional cli-
nicians from that practice can complete the REST train-
ing package, be added to the site delegation log and the
TRANSFoRm platform can be downloaded onto add-
itional practice computers.
Participants and eligibility
Eligible participants are children aged ≥ 12months to <
16 years whose parents/legal guardians are seeking pri-
mary medical care for acute-onset unilateral otorrhoea
Fig. 1 Trial flow chart
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as the presenting symptom of recent-onset (≤ 7 days)
AOM. Detailed inclusion and exclusion criteria are de-
tailed in Table 1.
Patient screening and recruitment
The process of patient screening and recruitment is de-
tailed below:
1. Children aged ≥ 12months to < 16 years
accompanied by a parent/legal guardian present to
their GP with suspected AOMd
2. GP invites parent and child to participate in the
REST study and provides a parent information
leaflet (child information leaflet for children over 6
years old)
3. GP seeks verbal agreement from parents and
assesses the child for eligibility using the TRAN
SFoRm electronic platform
4. Informed consent/assent is sought from parents of
eligible children, baseline data and contact details
are collected via the TRANSFoRm platform
5. Child is randomised using the TRANSFoRm
platform and, if allocated, the drops or immediate
antibiotics on an FP10 prescription (Standard UK
prescription) are issued.
Randomisation
After confirming eligibility and obtaining informed con-
sent, participants will be randomised (stratified by age)
to either (1) immediate topically administered ciproflox-
acin 0.3% drops with (2) delayed orally administered an-
tibiotics or (3) immediate orally administered antibiotics.
The randomisation sequence is generated by the Bris-
tol Randomised Trials Collaboration (BRTC) and sup-
plied to the TRANSFoRm electronic platform to be
allocated to each successive participant recruited. A sys-
tem for checking the correct randomisation allocation is
built in to the TRANSFoRm platform. Clinicians will not
be able to determine treatment allocation pre-
randomisation.
Consent
Parent Information Sheets (Additional file 2) will be
given to the parents of potentially eligible children and
discussed before consent is sought. Informed consent
will be obtained from the parent or legal guardian of
each child. Assent will be obtained from all children over
the age of 6 years. Parents will also be given be the op-
portunity to consent to stool-sample collections (with
the additional option of the sample being retained for
future research in microbial infections), declining to
consent to this element of the study will not exclude
participation from other elements of the study. Parents
will also be given the opportunity to consent to informa-
tion being collected about their child being used to sup-
port other research in the future, and to this being
shared anonymously with other researchers.
Table 1 Inclusion and exclusion criteria
Patient selection criteria
Inclusion criteria (child must
meet all criteria):
1. Children aged ≥ 12 months to <
16 years
2. Presenting with recent-onset (≤
7 days) unilateral AOM with recent-
onset (≤ 7 days) otorrhoea cur-
rently visible (or seen by parent/
legal guardian ≤ 24 h)
3. Child attending with parent/
legal guardian who is legally able
to give consent in person
4. Parent/legal guardian willing and
able to administer eardrops
5. Parent/legal guardian willing,
able and available to complete the
daily SRQ and received regular
telephone calls from the study
team
Exclusion criteria (excluded if
child meets any criterion at the
time of entry):
1. Symptoms/signs suggestive of
bilateral AOM/AOMd
2. Child has symptoms/signs
suggestive of serious illness and/or
complications, e.g. mastoiditis and/
or requires immediate
hospitalisation
3. Child requires immediate orally
administered antibiotics (e.g. for
another infection or AOMd
considered severe)
4. As per NICE guidelines [12], a
child at high risk of serious
complications:
• Significant immunosuppression
• Heart, lung, renal, liver or
neuromuscular disease (defined
as requiring ongoing inpatient
or outpatient care from specialist
teams) co-morbidities
• Trisomy 21 (Down’s syndrome),
cystic fibrosis or craniofacial
malformation, such as cleft
palate (these children are known
to be at higher risk of AOM)
5. Grommet (ventilation tube) in
situ in the ear with otorrhoea
6. Currently taking orally (for a
respiratory tract infection) or
topically administered (in the
affected ear) antibiotics
7. Allergy to ciprofloxacin
8. Allergy to penicillin/anaphylaxis
to another beta-lactam agent and
allergy to clarithromycin
9. Child has taken part in any
research involving medicines
within the last 90 days
10. Child has already participated
in this trial
AOM acute otitis media, SRQ Standard Recovery Questionnaire
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Withdrawal
Participants remain in the trial unless they choose to
withdraw, or if they are unable to continue. Parents can
choose to completely withdraw their child or to with-
draw from specific elements of the study without giving
a reason. Any data collected up until this point will be
retained for analysis. Information regarding the with-




We selected ciprofloxacin 0.3% drops as our topically
administered antibiotic because it:
 Is active against all common otopathogens [2]
 Is non-ototoxic
 Is widely and routinely available in the UK
 Is colourless so will not interfere with assessing
otorrhoea
 Will provide complementary evidence to the
ZonMw-funded trial, which is using an antibiotic-
steroid combination
We decided to avoid aminoglycoside drops because of
concerns about potential ototoxicity. We have proposed
delayed orally administered antibiotics as the second
intervention since our previous trials [1, 20, 21] have
achieved significant reductions in orally administered
antibiotic consumption compared with immediate anti-
biotic prescribing (and similar symptom relief). Immedi-
ate orally administered amoxicillin (clarithromycin if
allergic to penicillin) is the comparator as it reflects
usual care and is well-tolerated.
Intervention description
Arm 1: (control) current usual care – orally adminis-
tered amoxicillin suspension three times daily for 7 days
(or orally administered clarithromycin twice daily for 7
days if allergic to penicillin).
Arm 2: (intervention) antibiotic drops, to be instilled
three times daily into the discharging ear. Parents will be
given written advice regarding how to administer the
drops. This will include: (1) cleaning the outer ear of dis-
charge that can be easily removed with a tissue; (2) tilt-
ing the child’s head to one side (to approximately 90°)
when applying the eardrops; and (3) maintaining the tilt
for a few minutes to improve penetration of the drops.
Arm 3:(intervention) a ‘delayed’ prescription for orally
administered amoxicillin suspension antibiotics three
times daily for 7 days (or orally administered clarithro-
mycin twice daily for 7 days if allergic to penicillin). Par-
ents will be given written advice to delay the
prescription will consist of: (1) advising that the
prescription is only ‘dispensed’ at a pharmacy if symp-
toms worsen or are not starting to improve by 4 days;
and (2) safety-netting advice regarding the symptoms
that should prompt review consultation (increasing pain,
high temperatures, headaches, irritability or reduced
feeding).
All groups will also receive standard advice to
complete the antibiotic course and how to manage pain,
fever and other symptoms (e.g. use of paracetamol/
ibuprofen).
Post-trial care
Following participation in the study, children are
returned to usual care by their GP. All participants will
receive a summary of the results of the trial.
Outcome measures
The primary outcome measure is time to resolution of
the following symptoms: pain, fever, being unwell, sleep
disturbance, otorrhoea and episodes of distress. The pri-
mary outcome is the time until all symptoms are rated
by parents as ‘no’ or ‘very slight’ problem. This will be
recorded by parents in the Symptom Recovery Question-
naire (SRQ).
Secondary outcome measures:
 Duration of ‘moderately bad or worse’ symptoms
(pain, fever, being unwell, sleep disturbance,
otorrhoea; episodes of distress/crying
 Appetite and interference with normal activities up
to 14 days
 Antibiotic and analgesic use
 Adverse events – diarrhoea, rash, vomiting, serious
complications
 Treatment adherence
 Parent/legal guardian satisfaction with treatment
 NHS resource use at 14 days
 Repeat AOM and AOMd episodes, serious
complications and the OM6 hearing questionnaire
at 3 months;
 Qualitative evaluation of recruitment, medication
satisfaction, adherence and follow-up
 Analysis of stool sample to assess burden of
resistance
Assessment and follow-up
The components and timing of follow-up measures are
shown in Fig. 2.
Clinician-recorded outcomes: baseline data collection form
and contact form
During the consultation, clinicians will complete a base-
line data collection form and contact detail form for all
eligible participants. The baseline data collected includes
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acute clinical data and any relevant medical history relat-
ing to AOMd incidence.
A contact details form will record information from
the parent/legal guardian including name, address, tele-
phone number and availability to take calls from the re-
search nurse.
Patient-reported outcomes
All parents/legal guardians are asked to complete a daily
SRQ recording the symptoms identified by parents/legal
guardians as important. The SRQ will be provided in
electronic format via the TRANSFoRm app or in a paper
version. The SRQ will provide a daily record of symptom
burden and will be completed up to 14 days. The
primary outcome will be collected using the SRQ with
research nurse telephone calls on days 1, 3, 7, 10 and 14.
On day-7 and day-14 telephone calls, information on
the use of healthcare resources including information
about primary care contacts, use of 111, walk-in centres
and hospital services will be obtained.
At month 3, use of hospital services will be collected
by review of the patients’ EHR.
The final questionnaire will be sent 3 months after
randomisation either electronically (web or iOS/Android
app) via the TRANSFoRm platform or paper question-
naire. The questionnaire will ask about parent/legal
guardian-reported hearing loss at 3 months as measured
using the OM6 [22] questionnaire.
Fig. 2 Participant recruitment and follow-up timeline. *Completed daily from day 1 to day 14
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Storage and analysis of microbiological clinical samples
Plans for the collection, storage and evaluation of bio-
logical specimens can be found in Additional file 3.
Economic data collection
The economic evaluation will explore the relationship
between cost and outcomes for the three proposed
methods of treating AOMd. This will be done for the
short term (14 days) to assess the cost-effectiveness of
immediate topically or delayed orally administered anti-
biotics compared with immediate orally administered
antibiotics, and the longer term (3 months) in order to
capture the effects of any recurrence of symptoms and
lasting side effects. The perspectives will be from the
NHS, parents/carers, and lost productivity due to time
off work and school.
During the trial, participants will complete a symptom
diary which will record any use of healthcare resources
not available from the GP notes (for example, commu-
nity care and the use of 111 and walk-in centres) and
non-healthcare costs incurred by parents/carers during
the first 14 days such as travel costs, purchase of over-
the-counter medications, childcare and loss of earnings
due to time off work. We will also ask about time off
nursery/school.
Qualitative data collection
The qualitative evaluation will explore the views and ex-
periences of the trial processes, the acceptability of the
different treatment options, and the barriers and facilita-
tors to their use within, and future uptake outside the
trial.
Purposive sampling [23] will select participants in
order to capture maximum variation in views and expe-
riences of a range of parents and primary care profes-
sionals. From parents who agree to trial participation
and the interview, a purposive sample will be drawn in
relation to site, arm of the trial, and socio-demographic
variables such as socio-economic status. Parents who de-
cline trial participation will also be invited to be inter-
viewed. Primary care professionals involved in trial
processes will also be purposively sampled in relation to
site. Sample sizes will be determined by data saturation
[23], such that no new themes are emerging from the
data by the end of data collection. We anticipate includ-
ing up to 20 clinicians, 20 participant parent interviews
and 15 parent decliner/withdrawal telephone interviews.
In-depth interviews will be conducted with participat-
ing parents (from all arms of the trial) 14 days after ran-
domisation [24]. Interviews with parents who declined
to participate will be conducted within 7 of declining.
These will be conducted by telephone at a time of the
participant’s choosing. Interviews with primary care pro-
fessionals will be conducted after 3–6 months of
involvement in the trial to try to capture those with ex-
perience of recruitment. A flexible topic guide will be
devised to ensure that the primary issues are covered
across all interviews, but it will incorporate considerable
flexibility to enable participants to introduce unantici-
pated issues, and they will be modified to reflect findings
as they emerge. The researcher will use open-ended
questioning techniques to elicit participants’ experiences
and views of key events and participants will be asked to
provide examples. Primary care professional’s interviews
are expected to last around 30–45 min, parent interviews
30–40min and those with parents who decline trial par-
ticipation 10–20 min. Interviews will be recorded using a
digital voice recorder, transcribed and anonymised to
protect confidentiality.
Trial oversight
The study is overseen by a Trial Management Group
that meet on a monthly basis and consist of the chief in-
vestigator (CI), grant holders, study sponsor and any
other staff responsible for the delivery of the trial. The
Trial Steering Committee (TSC) provides independent
supervision of the trial and oversees trial progress. The
TSC consists of an independent chair and three other
independent members including a clinical trialist a stat-
istician, a Patient and Public Involvement (PPI) repre-
sentative and the CI. The Data Monitoring Committee
(DMC) monitors patient safety and trial data efficacy
and consists of an independent chair, three other inde-
pendent members and the CI.
All serious adverse events (SAE’S) are recorded and
notified as appropriate to the relevant authorities.
PPI
A comprehensive programme of PPI engagement was
conducted during the set-up stage to inform the devel-
opment of the symptom-diary data collection, of the par-
ent- and child-facing trial documentation. PPI
contributors attend both the Trial Management Group
(TMG) and Trial Steering Committee (TSC) meetings,
providing ongoing guidance. PPI members will help
identify non-academic dissemination avenues, and will
advise on materials for press releases, print media, social
media and parent-facing materials, including presenta-
tion of results using a parent/child-friendly animation.
Data management and confidentiality
Study data is collected and stored using the TRAN
SFoRm [19] GCP-validated clinical trial platform that is
integrated into the GP’s EHR system. Once a patient
presents to the GP with one of the specified otitis media
disease codes, eligibility screening is run in the back-
ground on their EHR. Should the patient be found suit-
able for inclusion in the study, the GP is asked to
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consent the patient/legal guardian. No data is captured
in TRANSFoRm until the parent/legal guardian has con-
sented to theirs and their child’s participation. The data
is captured through electronic Case Report Forms
(eCRFs) completed through the EHR system, and the Pa-
tient Reported Outcome Measures (PROMs) completed
at set time points by the patient through a web portal on
their mobile devices, tablets or desktop computers at
home. The data is transmitted using a secure connection
and stored inside an encrypted database hosted at King’s
College London. A subset of participant information is
additionally stored in the REDCap database hosted at
the University of Bristol, added by a member of the
REST study team.
Both the TRANSFoRm electronic platform and RED-
Cap incorporate data entry and validation rules to re-
duce data-entry errors and double data entry. Trial staff
will ensure that participant anonymity is maintained
through protective and secure handling and storage of
patient information at the trial centre’s. Data will be
anonymised as soon as it is practical to do so in line
with the Data Protection Act 1998. Participants’ data is
securely held on the databases in line with data protec-
tion legislation.
To comply with the Fifth Principle of the Data Protec-
tion Act 1998 (this process will be reviewed and updated
accordingly with any updates to the guidelines), personal
data will not be kept for longer than is required for the
purpose for which it has been acquired. Data will be held
in compliance with the sponsor’s standard operating
procedures.
Sample size
Our previous trial compared immediate with delayed
antibiotic use [1]. Children with AOMd took a median
of 3 days (interquartile range (IQR) 2, 4) to achieve the
REST primary outcome. Our PPI advised a 1.25-day
non-inferiority margin (equivalent to an absolute differ-
ence in cure rate of 19.5% at 3 days). A two-group non-
inferiority trial normally assumes a 2.5% one-sided Type
I error. Using a 1.25% Type I error to detect non-
inferiority for two comparisons with 90% power,
complete outcome data needed for 106 per arm is 399
with 20% attrition.
Statistical analysis
A flow of participants through the trial will be sum-
marised in a Consolidated Standards of Reporting Trials
(CONSORT) diagram. Descriptive statistics of baseline
clinical and socio-demographic characteristics will be
presented to describe the study sample and to ascertain
comparability of the randomisation groups.
Data from the internal pilot phase of the study will be
assessed against predefined/pre-agreed stop/go criteria
to inform the decision as to whether to continue the trial
to the ‘main’ phase. The proposed ‘traffic light’ (stop/go)
criteria are based on descriptive statistics summarising
recruitment, retention and adherence.
The primary analysis will be carried out under the
intention-to-treat (ITT) principle, analysing partici-
pants as randomised without the imputation of miss-
ing data. Kaplan-Meier survival curves will be
plotted to depict the probability of symptom reso-
lution over time. Symptom resolution over the 14
days of follow-up will be compared between children
allocated to immediate oral antibiotics and those al-
located to each of the other treatment groups using
a Cox proportional hazards regression model, ad-
justed for age (stratification variable). The primary
outcome will also be analysed using an Accelerated
Failure Time (AFT) model, which has previously
been recommended for studies of resolution of infec-
tious diseases as previous research has suggested that
symptoms of AOM will be resolved in 90% of chil-
dren by day 8.
The proportion of participants in the immediate topic-
ally and delayed orally administered antibiotics arms
who achieve symptom resolution within 3 days will be
compared (separately) to those in the immediate orally
administered antibiotics arm. The absolute difference
will be calculated and reported alongside the associated
confidence interval, it will then be reported as to
whether or not the lower limit of the confidence interval
lies within the maximum unimportant difference.
Analysis of secondary outcomes will utilise regression
models appropriate for the nature of the outcome meas-
ure (i.e. logistic regression for binary outcomes, Poisson
or negative binomial regression for count data).
The primary analysis model will be repeated but
with the outcome of symptom resolution being de-
fined as when all symptoms are rated as being ‘nor-
mal/none’, ‘very slight problem’ or ‘slight problem’
(compared to the primary outcome of symptom reso-
lution being defined as all symptoms being rated as
‘normal/none’ or ‘very slight problem’). The primary
analysis will also be repeated under the per-protocol
approach (rather than ITT). The sensitivity of the pri-
mary analysis to the impact of missing data will also
be explored by repeating the analysis after the imput-
ation of missing primary outcome data. The primary
analysis and AFT model will be repeated with add-
itional adjustment for any prognostic variable showing
a marked imbalance at baseline (ascertained using de-
scriptive statistics). Baseline characteristics will be in-
vestigated as potential treatment effect moderators,
this will be done by including treatment group by
moderator interaction terms into the primary analysis
model (individually).
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Economic data analysis
The primary economic evaluation will explore the rela-
tionship between cost and outcome for the three treat-
ments for AOMd (immediate topically, delayed orally
and immediately administered oral antibiotics) from an
NHS perspective at 14 days post randomisation. This
will take the form of a simple comparison of NHS costs
and outcomes over a period of 2 weeks from
randomisation.
A secondary cost analysis will evaluate the difference
in NHS secondary care costs between the trial arms for
the 3 months following randomisation.
All resources will be valued using unit costs from
established sources. These will include Unit Costs of
Health and Social Care [25] for primary and community
care, NHS Reference Costs [26] for hospital care and the
BNFC [27] for prescribed medication.
Differences in NHS resources and costs between the
arms will be analysed initially using Ordinary Least
Squares (OLS) regression. The distribution of residuals
from the regression models will then be examined and a
decision will be made as to whether OLS is appropriate
or another type of regression model should be consid-
ered (e.g. Generalised Linear Models (GLM)).
A cost-consequence analysis will then be conducted in
which the costs to the NHS of the three treatments at
14 days post randomisation will be compared with the
primary clinical outcome. Areas of uncertainty in as-
sumptions will be subjected to sensitivity analyses to test
the robustness of the results.
Qualitative data analysis
Interview transcripts will be imported into NVivo 12
qualitative data analysis software. Analysis will begin
shortly after data collection starts and will be ongoing
and iterative – informing further data collection and
identifying changes needed to the topic guide. Thematic
analysis [28], utilising a data-driven inductive approach,
will be used to identify and analyse patterns and themes
of particular salience for participants and across the
dataset using constant-comparison techniques [29, 30].
A subset of transcripts will be independently double-
coded by members of the team (CC and JH); any dis-
crepancies will be discussed within the team and re-
solved to achieve coding consensus and maximal rigour.
Blinding
Once the allocation is revealed, neither clinicians nor
the child participant or their parent/legal guardian will
remain blind to their allocated treatment. Codes will be
assigned to the database, which will preserve blinding of
study personnel. The senior statistician will remain blind
to knowledge of which treatment is represented by each
treatment code until the final results have been shared
with the Data Monitoring Committee (DMC). Emer-
gency unblinding will not be necessary in this trial since
it is an open study.
Dissemination
We will publish the trial results in peer-reviewed jour-
nals and present at national and international meetings.
With the assistance of our collaborators and PPI we will
disseminate the study findings to an international audi-
ence. All participants will be offered a lay summary of
the main findings of the study.
Discussion
This article outlines a pragmatic, three-arm, individually
randomised trial, which aims to recruit from 175 GP
practices across the UK. The aim is to establish evidence
for the non-inferiority of: (1) immediate topical ear
drops, ciprofloxacin 0.3%; (2) delayed orally administered
amoxicillin (clarithromycin) or (3) immediate orally ad-
ministered amoxicillin (clarithromycin). The non-
inferiority will be based on time to resolution of all sig-
nificant symptoms. Secondary outcomes will include
cost-effectiveness, duration of moderately bad or worse
symptoms and repeat AOMd episodes.
Recruitment of 399 children with AOMd over a 22-
month period presented challenges around the design of
the REST study. Only two to three patients’ children
were expected to present at each GP practice over the
22-month recruitment period, requiring at least 175 GP
practices to take part in the study.
In order to make this study feasible we needed to con-
sider novel and streamline mechanism to facilitate
greenlighting of sites, training of site staff, identification
of eligible participants and the collection of high-quality
data.
We employed several different strategies in order to
address these elements of the study, these included:
 Development of a remote training platform to
deliver REST study training to GPs and staff at
recruiting practices
 A light-touch Green Light Process (GLP), maximis-
ing the number of staff at the GP practices able to
recruit to the REST study by providing quick and
accessible study-specific training
We used the TRANSFoRm electronic platform, (inte-
grates into the health records) to automatically create a
pop-up alert to the clinician when an eligible patient
presents. The system automatically checked the partici-
pant’s eligibility and part-filled the study eCRFs reducing
the efforts of the clinician to record study data.
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Trial status
Currently, 50 SystmOne GP practices have been green-
lighted across seven CRN regions in the UK. The first
child was recruited to the study on 5 April 2019 with re-
cruitment currently ongoing. A total of 22 children were
recruited to the REST study, with recruitment being
closed on 31 May 2020.
Protocol: Version 7.0, 31 October 2018
Open to recruitment: 7 April 2019
Planned recruitment closure date: 31 March 2020
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